• Cardiology, Diabetes & Nephrology
    • Cardiology, Diabetes & Nephrology – London
    • Cardiology, Diabetes & Nephrology – Brazil
    • Cardiology, Diabetes & Nephrology – Canada
    • Cardiology, Diabetes & Nephrology – USA
    • Hatter Horizon Series
    • The 18th Malvern Diabetic Foot Conference
    • Previous Events
      • CDNATL 2019 – London
      • CDNATL 2019 – Brazil
      • CDNATL 2018
      • CDNATL 2017
      • CDNATL 2016
      • CDNATL 2015
      • CDNATL 2014
      • CDATL 2013
      • CDATL 2012
      • NATL 2012
      • CDATL 2011
      • CDATL 2010
      • NATL 2010
      • CATL 2009
      • NATL 2009
  • Cell Therapy
    • Cell Therapy at the Limits 2021
  • Oncology
    • Previous Events
      • Accelerating Cancer Immunotherapy 2017
      • OATL 2016
      • OATL 2015
      • OATL 2014
      • OATL 2012
      • OATL 2011
      • OATL 2010
      • UCL Frontiers of Oncology 2019
        • Haematology
        • Melanoma
        • Urology
        • Women’s Health
        • Lung Cancer
        • Gastrointestinal Oncology
  • Multiple Sclerosis
    • Multiple Sclerosis at the Limits 2021
    • Multiple Sclerosis Nurses at the Limits 2021
    • Previous events
      • Multiple Sclerosis at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2019
      • MSATL 2018: Introduction
      • MSATL 2017: Introduction
  • About
    • Academic Founders
    • Independence
    • The Lancet
    • Support & Sponsorship
    • Delegate Invitations
  • Supporters
  • Archive
    • CDNATL 2019 – London
    • CDNATL 2019 – Brazil
    • Multiple Sclerosis at the Limits 2018
    • Multiple Sclerosis at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2019
    • Hatter Horizon Series
      • Horizon GP Programme 2019
      • Hatter Horizon Series 2019
      • Hatter Horizon Series 2018
      • Hatter Horizon Series 2017
    • Cardiology, Diabetes & Nephrology at the Limits 2018
    • Accelerating Cancer Immunotherapy 2017
    • Oncology at the Limits 2017

OATL 2015: Event now closed

OATL-Logo-new-purple-photoshop-HUGE-psd

The OATL 2015 event is now closed
The 2016 dates and venue will be announced during March 2015.

 

The multimedia archive of the 2015 event can be viewed by clicking here.

Cardiology, Diabetes & Nephrology at the Limits Brazil
Thursday 21 & Friday, 22 October 2021, Virtual Meeting

Hatter Horizon GP Meeting
Monday, 1 November 2021
London, UK

Hatter Horizon Series
Monday, 22 November 2021, London, UK

Cardiology, Diabetes & Nephrology at the Limits 2022
Monday, 4 & Tuesday, 5 April 2022, London,UK

Cell Therapy at the Limits 2022
June 2022, London, UK

The 19th Malvern Diabetic Foot Conference
Wednesday, 11 - Friday, 13 May 2022, Malvern, UK

Multiple Sclerosis Nurses
at the Limits
Friday, 16 & Saturday, 17 September 2022, London, UK

Multiple Sclerosis at the Limits
Tuesday, 27 & Wednesday, 28 September 2022, London, UK

Cardiology, Diabetes & Nephrology at the Limits Japan
Saturday 15th & Sunday 16th October 2022, Tokyo, Japan

Cardiology, Diabetes & Nephrology at the Limits Canada
Q3 2022, Toronto, Canada

Pages

  • DJ test
  • MSTV
  • Homepage
    • /cdnatl2021
    • Announcements
    • CDNATL2019
    • Corporate Hospitality
    • Professor Lionel Opie – Obituary from The Lancet
    • Chairs
    • The ATL Series
    • The Lancet Editorial
    • Core Principles – Education for Africa
    • Independence
    • Academic Founders
  • Oncology
    • OATL 2016
      • OATL 2016: CME Accreditation
      • OATL 2016: Conflict of Interest forms
      • OATL 2016: Delegate Feedback
      • OATL 2016: Chairpersons
      • OATL 2016: Dr Richard Horton Video
      • OATL 2016: Self Funded Registration
      • OATL 2016: Venue
      • OATL 2016: Introduction
      • The Lancet Oncology/Haematology – Fully Funded Places Offer
      • OATL 2016: Schedule
      • OATL 2016: Programme
      • OATL 2016: Information
      • OATL 2016: Hotel
    • Oncology at the Limits: Delegate feedback 2009 to 2014
    • OATL 2017
      • OATL 2017: CME Accreditation
      • OATL 2017: Conflict of Interest forms
      • OATL 2017: Delegate Feedback
      • OATL 2017: Registration
      • OATL 2017: Chairs
      • OATL 2017: Venue
      • OATL 2017: Introduction
      • OATL 2017: Schedule
      • OATL 2017: Programme
      • OATL 2017: Information
      • OATL 2017: Hotel
    • OATL 2018: Introduction
    • OATLC 2018: Introduction
    • OATL Event Closed
      • OATL 2014: Event now closed
      • OATL 2015: Event now closed
        • OATL 2015: Affiliate Feedback
      • OATL 2012: Event now closed
      • OATL 2011: Event now closed
      • OATL 2010: Event now closed
  • Delegate Invitations
  • Disclosure
  • Sprint 1 Registration
  • UKONS / Gilead Symposium Presentations
  • General Data Protection Regulations – Opt In
  • General Data Protection Regulations Contact
  • Multiple Sclerosis
    • MSATL 2017: Introduction
      • MSATL 2017: CME Accreditation
      • MSATL 2017: Conflict of Interest Forms
      • MSATL 2017: Day Delegate Registration
      • MSATL 2017: Delegate Registration
      • MSATL 2017: European Delegate Registration
      • MSATL 2017: European Delegate Reimbursement
      • MSATL 2017: Faculty Registration
      • MSATL 2017: Faculty Registration
      • MSATL 2017: Staff Registration
      • MSATL 2017: Student Registration
      • Multiple Sclerosis at the Limits 2017
      • Reimbursement
      • Reimbursement
      • MSATL 2017: Chairs
      • MSATL 2017: Venue
      • MSATL 2017: Schedule
      • MSATL 2017: Programme
      • MSATL 2017: Supporters
      • MSATL 2017: Hotel
      • MSATL 2017: Information
    • MSATL 2018: Introduction
      • MSATL 2018: Pre-register
      • MSATL 2018: CME Accreditation
      • MSATL 2018: Conflict of Interest Forms
      • MSATL 2018: Delegate Registration
      • MSATL 2018: Delegate Registration
      • MSATL 2018: Delegate Registration
      • MSATL 2018: Delegate Registration
      • MSATL 2018: EUR Reimbursement
      • MSATL 2018: Faculty Registration
      • MSATL 2018: Faculty Registration
      • MSATL 2018: GBP Reimbursement
      • MSATL 2018: Nominate Colleagues
      • MSATL 2018: Nominate Nurses for MSNATL 2019
      • MSATL 2018: Registration
      • MSATL 2018: Staff Registration
      • MSATL 2018: Student Registration
      • MSATL 2018: Chairs
      • MSATL 2018: Venue
      • MSATL 2018: Schedule
      • MSATL 2018: Programme
      • MSATL 2018: Supporters
      • MSATL 2018: Hotel
      • MSATL 2018: Information
    • MSATL 2020: Introduction
      • MSATL 2020: Faculty Registration
      • MSATL 2020: Faculty Registration
    • MSNATL 2019: Introduction
      • MSNATL 2019: Express Interest
      • MSNATL 2019: Conflict of Interest Forms
      • MSNATL 2019: Nominate Colleagues
      • MSNATL 2019: Delegate Registration
      • MSNATL 2019: Delegate Registration
      • MSNATL 2019: Delegate Registration
      • MSNATL 2019: EUR Reimbursement
      • MSNATL 2019: Faculty Registration
      • MSNATL 2019: Faculty Registration
      • MSNATL 2019: GBP Reimbursement
      • MSNATL 2019: Registration
      • MSNATL 2019: Staff Registration
      • MSNATL 2019: Student Registration
      • MSNATL 2019: Chairs
      • MSNATL 2019: Venue
      • MSNATL 2019: Programme
      • MSNATL 2019: Supporters
      • MSNATL 2019: Schedule
      • MSNATL 2019: Hotel
      • MSNATL 2019: Information
    • MSNATL 2020: Introduction
      • MSNATL 2020: Faculty Registration
      • MSNATL 2020: Faculty Registration
    • MSNATL 2019: Information
  • CDN2018
  • The Lancet – Fully funded places offer
  • Accelerating Cancer Immunotherapy
    • ACI Programme
    • ACI Chairs
    • Pre-Register – ACI Europe 2020
    • Sponsor Registration
    • Sponsor Registration
    • ACI 2017 Venue
    • ACI 2017: Supporters
  • Multimedia
    • Cardiology, Diabetes & Nephrology at the Limits 2017: Multimedia
      • Debate – (For: Professor Iain Macdougall – Against: Dr Marc Pfeffer): Strategies for optimising haemoglobin in CKD (both pre and post dialysis) & CV Disease. What level and how to get there?
      • Dr C Noel Bairey Merz: Is it time to look at microvascular angina? Are these the new limits?
      • Dr Chris Winearls: eGFR & CKD Staging. Better understanding or a struggle with the law of unintended consequences?
      • Dr Daniel Lenihan: Cardio-Oncology – preventing the cancer patient of today being the heart failure patient of tomorrow!
      • Dr Peter Libby: Novel concepts of the pathogenesis of the acute coronary syndromes.
      • Dr Steven Weisbord: rials and tribulations in AKI. Do we know where we are going?
      • Professor Allison Goldfine: GLP-1 analogues & DPPIV Inhibitors – are there new limits for beneficial cardiovascular outcome in type 2 diabetes?
      • Professor Bernard Gersh: PCI vs CABG for multi-vessel and left main coronary disease – do we have the evidence?
      • Professor David Wheeler: Diabetes & the kidney: BP control-how low can you go?
      • Professor Gerd Heusch: The preconditioning phenomenon – lost in translation?
      • Professor John Wilding: SGLT2 inhibition – a novel strategy to improve type 2 diabetes, cardiovascular & renal outcome
      • Professor Kausik Ray: PCSK9 inhibition – have we reached the limits of lipid lowering and outcome?
      • Professor Liesl Zühlke: The prevention, management and control of rheumatic heart disease: are we at the limits?
      • Professor Naomi Levitt: The global burden of diabetes.
      • Professor Natan Bornstein: What is the connection between the heart and the brain?
      • xxx: yyy
    • Cardiology, Diabetes & Nephrology at the Limits 2018: Multimedia
    • Cardiology, Diabetes & Nephrology at the Limits 2019: Multimedia
    • CDNATL 2019: Vifor Symposium
    • Hatter Horizon Series 2017
      • The global burden of diabetes – Professor Paul Zimmet
    • Hatter Horizon Series 2018: Multimedia
    • Multiple Sclerosis at the Limits 2018: Multimedia
    • Multiple Sclerosis Nurses at the Limits 2019: Multimedia
    • Accelerating Cancer Immunotherapy 2017: Multimedia
      • Dr Alena Gros Vidal: Targeting the cancer mutanome
      • Dr Christian Blank: Emerging approaches in melanoma immunotherapy
      • Dr James Larkin: Ongoing development of checkpoint trials
      • Dr James P. Allison: Immune checkpoint in cancer therapy: New insights into mechanism
      • Dr Jerome Galon: The tumor microenvironment and the dynamics of the immune response in human tumors
      • Dr Padmanee Sharma: From the clinic to the lab: Investigating mechanisms of response and resistance to immune checkpoint therapy
      • Dr Ramy Ibrahim: Trends & Collaborations in the IO Space
      • Dr Sergio Quezada: Deciphering immune regulation and recognition at the tumour site
      • Professor Alan Melcher: Immuno-oncolytic viruses as cancer therapies
      • Professor Alexander MM Eggermont: Immune biomarkers and measuring response
      • Professor Crystal Mackall: Immune-based therapies for childhood cancer
      • Professor Richard Sullivan: The affordability of the extraordinary
      • Professor Robert Schreiber: Eradicating tumors using the immune system
      • Professor Tim Illidge: Radiation treatment and immunotherapy combinations to improve outcome for cancer patients
    • Oncology at the Limits 2017: Multimedia
      • Dr David Meek: How p53 can contribute to protecting cells from DNA damage
      • Dr Roy Herbst: Personalized immunotherapy for advanced non-small cell lung cancer
      • Dr Silvia von Karstedt: The biology of the TRAIL system in cancer and the associated discovery of combination therapies
      • Dr W. Mark Saltzman: Using nanoparticles for drug delivery
      • Professor Charles Swanton: Sequencing cancer genomes and personalising cancer treatments
      • Professor Christian Rolfo: Cancer and the microbiome: potential applications as a new tumor biomarker
      • Professor Dr Ambros Beer: Hybrid imaging and advances in nuclear medicine
      • Professor Eyal Gottlieb: How Metabolism affects cell growth in cancer
      • Professor Joann B. Sweasy: DNA repair in Cancer
      • Professor John Hartley: The development of novel cancer therapies involving DNA as a target
      • Professor Melinda L. Irwin: Examining the effect of exercise and weight loss on cancer biomarkers, treatment side effects and quality of life
      • Professor Rene Bernards: Synthetic lethal screens for rational drug combinations
      • Professor Tony Ng: State of the art in Molecular Imaging
      • Professor Uwe Oelfke: The next generation of radiotherapy treatment
    • Cardiology, Diabetes and Nephrology at the Limits 2016: Multimedia
      • Dr Dariush Mozaffarian: A global perspective in preventing cardiovascular disease from discovery to policy
      • Dr Joseph Bonventre: How might we be preventing acute kidney injury in 2025?
      • Dr Julian Gillmore: Amyloid- a cardiorenal disease
      • Dr Laura Mauri: Debate: Dual anti-platelet therapy post drug eluting stents – what should the limits be? Long term effects
      • Dr Rick Johnson: Fructose, urate, life and death
      • Dr Stephen Wiviott: Sodium-glucose co-transporter inhibitors, incretins, glitazones – a cardiologist’s perspective on choice and limitations
      • Prof. Dr. med. Thomas F. Lüscher: Debate: Dual anti-platelet therapy post drug eluting stents – what should the limits be? Short term effects
      • Professor Bernard Gersh: The Epidemic of Atrial Fibrillation: Is it a vascular disease?
      • Professor Jim Mann: Obesity, coronary heart disease and diabetes; Lipids vs Carbohydrates at the limits
      • Professor John Chapman: PCSK9 inhibitors-a new approach to cholesterol homeostasis – are we approaching the limits?
      • Professor John Deanfield: Preventative cardiology in youth – what are the limits?
      • Professor John McMurray: Heart failure therapy – extending the limits!
      • Professor Rajiv Agarwal: Treating the kidney protecting the heart-what are the limits?
      • Professor Valentin Fuster: The PolyPill – a new therapeutic approach
    • Oncology at the Limits 2016: Multimedia
      • Dr Daniel P. Petrylak: Immunotherapy in bladder cancer: research at the limits
      • Dr Jeff Geschwind: Image guided therapy of Hepatomas
      • Dr Mario Sznol: Cancer immunotherapy affecting patients with unresectable stage III or stage IV malignant melanoma
      • Dr Mark Lemmon: Extracting clues for developing new EGFR inhibitory approaches in cancer
      • Dr Rita Nanda: Immunotherapy for the treatment of triple-negative breast cancer
      • Prof. Dr. med. Stephanie E. Combs: High-precision radiotherapy and the integration of modern imaging techniques
      • Professor Ajay Vora: Childhood ALL in the UK: Treatment at the Limits
      • Professor Alan Ashworth: Using functional genomics to identify genes that modify the tumor cell response to therapy
      • Professor Alison Lloyd: The cellular complexity of nerve regeneration- implications for nerve repair and tumourigenesis
      • Professor Andrew Biankin: Novel Personalised Therapeutic Strategies in Pancreatic Cancer
      • Professor Bart Vanhaesebroeck: Isoforms of PI 3-kinase in cancer
      • Professor Fabrice Andre: Targeted therapy in Breast Cancer matched to individuals’ genomic alterations
      • Professor Rebecca Fitzgerald: Early detection and treatment of cancer of the oesophagus
      • Professor Robert Hawkins: T-cell mediated immunotherapies for Cancer
      • Professor Roger Stupp: Alternating electric fields and other advances for treatment of glioma
      • Professor Ruth Plummer: Phase 1 trial design
  • Support & Sponsorship
  • Secure Connection Issues, potential fix
  • Feedback
    • CDNATL 2018: Feedback
    • CDNATL 2019: Feedback
    • FOC 2019: Feedback
    • FOW 2017: Feedback
    • Gilead – Cardiff 2018: Feedback
    • Gilead – Glasgow 2018: Feedback
    • Gilead – Ireland 2018: Feedback
    • Gilead – London 2018: Feedback
    • Gilead – Oxford 2018: Feedback
    • HGP 2019: Feedback
    • HHS 2017: Feedback
    • HHS 2018: Feedback
    • MDFC 2018: Feedback
    • MSATL 2017: Feedback
    • MSATL 2018: Feedback
    • MSNATL 2019: Feedback
  • 1st British Symposium on Diabetic Neuropathy
  • Accept Invite
  • Data Protection
  • Decline Invite
  • Historic Multimedia
  • Medical Disclaimer
  • Biographies
  • Register Interest
  • Roche Feedback
  • Supporters: 2017
  • Supporters: 2016
  • Supporters
  • Supporters: 2018
  • Contact
  • Cookie Policy
  • Privacy Policy
  • Earnings Disclaimer
  • E-mail Policy
  • External Links Policy
  • Dmca Notice
  • Disclaimer
  • Anti-spam Policy
  • Terms of use
  • CDNATL 2015: Event now closed
  • CDATL 2014: Event now closed
  • CDATL 2013: Event now closed
  • CDATL 2012: Event now closed
  • CDATL 2011: Event now closed
  • CDATL 2010: Event now closed
  • CATL 2009: Event now closed
  • CDNATL 2016: Delegate Feedback
  • CDNATL 2016: Horton Industry
  • CDNATL 2016: Academic Structure
  • CDNATL 2016: Introduction
  • CDNATL 2016: Venue
  • CDNATL 2016: Programme
  • CDNATL 2016: Chairpersons
  • CDNATL 2016: Hotel
  • CDNATL 2016: Information
  • CDNATL 2016: Schedule
  • CDNATL 2017: Conflict of Interest forms
  • CDNATL 2017: Directions
  • CDNATL 2017: CME Accreditation
  • CDNATL 2017: Chairs
  • CDNATL 2017: Information
  • CDNATL 2017: Programme
  • CDNATL 2017: Schedule
  • CDNATL 2017: Venue
  • CDNATL 2017: Delegate Feedback
  • CDNATL 2017: Delegate Feedback
  • CDNATL 2017: Hotel
  • CDNATL 2018: Agent Staff Registration – Novo Nordisk
  • CDNATL 2018: Delegate Registration
  • CDNATL 2018: Delegate Registration
  • CDNATL 2018: Delegate Registration
  • CDNATL 2018: Delegate Registration – AIIMS
  • CDNATL 2018: Delegate Registration – Novo Nordisk
  • CDNATL 2018: Delegate Registration – Novo Nordisk
  • CDNATL 2018: Delegate Registration – Novo Nordisk
  • CDNATL 2018: Delegate Registration – Novo Nordisk
  • CDNATL 2018: Delegate Registration – UK
  • CDNATL 2018: Faculty Registration
  • CDNATL 2018: Faculty Registration
  • CDNATL 2018: Registration – Day
  • CDNATL 2018: Reimbursement – EU
  • CDNATL 2018: Reimbursement – UK
  • CDNATL 2018: Staff Registration – Novo Nordisk
  • CDNATL 2018: Staff Registration – Novo Nordisk
  • CDNATL 2018: Staff Registration – Novo Nordisk
  • CDNATL 2018: Staff Registration – Novo Nordisk
  • CDNATL 2018: Staff Registration – Novo Nordisk
  • CDNATL 2018: Student Registration
  • CDNATL 2018: Symposium Registration
  • CDNATL 2018: Vifor Symposium
  • Conflict of Interest forms
  • CDNATL 2018: CME Accreditation
  • CDNATL 2018: Venue
  • CDNATL 2018: Programme
  • CDNATL 2018: Scientific Committee
  • CDNATL 2018: Hotel
  • CDNATL 2018: Information
  • CDNATL 2018: Schedule
  • CDNATL 2018: Supporters
  • CDNATL 2019: Delegate Registration
  • CDNATL 2019: Delegate Registration – NN – Europe
  • CDNATL 2019: Delegate Registration – NN – Rest of World
  • CDNATL 2019: Delegate Registration – NN – UK
  • CDNATL 2019: Delegate Registration – NN – UK Day
  • CDNATL 2019: Delegate Registration – The Lancet D&E
  • CDNATL 2019: Delegate Registration – Vifor
  • CDNATL 2019: Delegate Registration – Vifor Symposium
  • CDNATL 2019: Faculty Registration
  • CDNATL 2019: Faculty Registration
  • CDNATL 2019: Programme
  • CDNATL 2019: Reimbursement
  • CDNATL 2019: Staff Registration
  • CDNATL 2019: Staff Registration – Napp
  • CDNATL 2019: Staff Registration – NN
  • CDNATL 2019: Staff Registration – NN
  • CDNATL 2019: Staff Registration – Vifor
  • CDNATL 2019: Student Registration
  • CDNATL 2019: Schedule
  • CDNATL 2019: Venue
  • CDNATL 2019: Hotel
  • CDNATL 2019: Scientific Committee
  • CDNATL 2019: Supporters
  • CDNATL 2019: CME Accreditation
  • CDNATL 2019: Conflict of Interest Forms
  • CDNATL 2019: Information
  • CDNATL 2020: Affiliate Registration – Novo Nordisk
  • CDNATL 2020: Delegate Registration
  • CDNATL 2020: Delegate Registration – Novo Nordisk
  • CDNATL 2020: Delegate Registration – Novo Nordisk
  • CDNATL 2020: Delegate Registration – Novo Nordisk
  • CDNATL 2020: Delegate Registration – Novo Nordisk
  • CDNATL 2020: Faculty Registration
  • CDNATL 2020: Faculty Registration
  • CDNATL 2020: Reimbursement
  • CDNATL 2020: Staff Registration
  • CDNATL 2020: Staff Registration – Novo Nordisk
  • CDNATL 2020: Staff Registration – Novo Nordisk
  • CDNATL 2021: Programme
  • CDNATL 2021: Schedule
  • CDNATL 2021: Venue
  • CDNATL 2021: Hotel
  • CDNATL 2020: Scientific Committee
  • CDNATL 2020: CME Accreditation
  • CDNATL 2021: Express Interest
  • CDNATL 2021: Express Interest
  • CDNATL 2020: Supporters
  • CDNATL 2021: Information
  • CDNB 2019: Brazil Media
  • CDNB 2019: Delegate Registration
  • CDNB 2019: Delegate Registration
  • CDNB 2019: Delegate Registration
  • CDNB 2019: Delegate Registration
  • CDNB 2019: Delegate Registration
  • CDNB 2019: Delegate Registration
  • CDNB 2019: Delegate Registration
  • CDNB 2019: Delegate Registration
  • CDNB 2019: English Media
  • CDNB 2019: Faculty Registration
  • CDNB 2019: Faculty Registration
  • CDNB 2019: Media Menu
  • CDNB 2019: Programme
  • CDNB 2019: Reimbursement
  • CDNB 2019: Staff Registration
  • CDNB 2019: Student Registration
  • CDNB 2019: Unicamp Registration
  • CDNB 2019: Schedule
  • CDNB 2019: Venue
  • CDNB 2019: Conference Hotel
  • CDNB 2019: Scientific Committee
  • CDNB 2019: Express Interest
  • CDNB 2019: Supporters
  • CDNB2019: Conflict of Interest Forms
  • CDNB 2019: Information
  • CDNATL 2015
  • CDNATL 2015: Affiliate Feedback
  • CDNATL 2015: Delegate Feedback
  • CDNATL 2016
  • CDNATL 2017: Introduction
  • CDNATL 2019: Introduction
  • CDNB 2019: Introduction
  • CDNATL 2018: Introduction
  • CDNATL 2021: Introduction
  • CDNATL Event Closed
  • NATL 2012: Event now closed
  • NATL 2010: Event now closed
  • NATL 2009: Event now closed

Archives

  • March 2020
  • July 2019
  • February 2019

Categories

  • At the Limits (5)
    • Announcements (5)
    • Events (5)
      • CDNATL (5)

WordPress

  • Log in
  • WordPress
  • Contact
  • The Lancet
  • UCL
  • UCT
  • Brigham & Women’s Hospital
  • The University of Campinas
© 2021 At the Limits Ltd.
This site uses cookies More info